Alpha-eleostearic acid suppresses proliferation of MCF-7 breast cancer cells via activation of PPARγ and inhibition of ERK 1/2

Hyun-Seuk Moon, Ding Ding Guo, Hong Gu Lee, Yun Jaie Choi, Jae Seong Kang, Kyungmin Jo, Jung Min Eom, Cheol Heui Yun, Chong Su Cho

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Alpha-eleostearic acid (α-ESA) is known to suppress the growth in cancer cells although its underlying molecular mechanisms have not been fully elucidated. The present study was designed to elucidate and evaluate the anticancer mechanism of α-ESA on MCF-7 breast cancer cells. Also, an attempt was made to better understand the anticancer mechanism by which α-ESA activated PPARgamma; and attenuated the ERK1/2 MAPK phosphorylation state. The MCF-7 breast cancer cell-line and nontumorigenic MCF-10A human mammary epithelial cells were treated with α-ESA and compared with negative control (without treatment) and positive control groups (treated with rosiglitazone), and changes of apoptosis-related molecules, PPARgamma; and pERK1/2 were examined. In MCF-7 cells treated with α-ESA, we found that the expression of p53, p21, and Bax was up-regulated whereas expression of Bcl-2 and procaspase-9 was down-regulated. Moreover, nuclear translocation of PPARγ by α-ESA positively correlated with inhibition of ERK1/2 activation. Our data suggest that α-ESA can be considered to be a PPARgamma; agonist and thus a candidate for a chemotherapeutic agent against breast cancer.

Original languageEnglish
Pages (from-to)396-402
Number of pages7
JournalCancer Science
Volume101
Issue number2
DOIs
Publication statusPublished - 2010 Feb 1
Externally publishedYes

Fingerprint

Peroxisome Proliferator-Activated Receptors
PPAR gamma
rosiglitazone
Breast Neoplasms
Caspase 9
MCF-7 Cells
Breast
Epithelial Cells
Phosphorylation
Apoptosis
Cell Line
Control Groups
Growth
eleostearic acid
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Alpha-eleostearic acid suppresses proliferation of MCF-7 breast cancer cells via activation of PPARγ and inhibition of ERK 1/2. / Moon, Hyun-Seuk; Guo, Ding Ding; Lee, Hong Gu; Choi, Yun Jaie; Kang, Jae Seong; Jo, Kyungmin; Eom, Jung Min; Yun, Cheol Heui; Cho, Chong Su.

In: Cancer Science, Vol. 101, No. 2, 01.02.2010, p. 396-402.

Research output: Contribution to journalArticle

Moon, Hyun-Seuk ; Guo, Ding Ding ; Lee, Hong Gu ; Choi, Yun Jaie ; Kang, Jae Seong ; Jo, Kyungmin ; Eom, Jung Min ; Yun, Cheol Heui ; Cho, Chong Su. / Alpha-eleostearic acid suppresses proliferation of MCF-7 breast cancer cells via activation of PPARγ and inhibition of ERK 1/2. In: Cancer Science. 2010 ; Vol. 101, No. 2. pp. 396-402.
@article{e6b981586bd347efb3f8ebbca61f1d06,
title = "Alpha-eleostearic acid suppresses proliferation of MCF-7 breast cancer cells via activation of PPARγ and inhibition of ERK 1/2",
abstract = "Alpha-eleostearic acid (α-ESA) is known to suppress the growth in cancer cells although its underlying molecular mechanisms have not been fully elucidated. The present study was designed to elucidate and evaluate the anticancer mechanism of α-ESA on MCF-7 breast cancer cells. Also, an attempt was made to better understand the anticancer mechanism by which α-ESA activated PPARgamma; and attenuated the ERK1/2 MAPK phosphorylation state. The MCF-7 breast cancer cell-line and nontumorigenic MCF-10A human mammary epithelial cells were treated with α-ESA and compared with negative control (without treatment) and positive control groups (treated with rosiglitazone), and changes of apoptosis-related molecules, PPARgamma; and pERK1/2 were examined. In MCF-7 cells treated with α-ESA, we found that the expression of p53, p21, and Bax was up-regulated whereas expression of Bcl-2 and procaspase-9 was down-regulated. Moreover, nuclear translocation of PPARγ by α-ESA positively correlated with inhibition of ERK1/2 activation. Our data suggest that α-ESA can be considered to be a PPARgamma; agonist and thus a candidate for a chemotherapeutic agent against breast cancer.",
author = "Hyun-Seuk Moon and Guo, {Ding Ding} and Lee, {Hong Gu} and Choi, {Yun Jaie} and Kang, {Jae Seong} and Kyungmin Jo and Eom, {Jung Min} and Yun, {Cheol Heui} and Cho, {Chong Su}",
year = "2010",
month = "2",
day = "1",
doi = "10.1111/j.1349-7006.2009.01389.x",
language = "English",
volume = "101",
pages = "396--402",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Alpha-eleostearic acid suppresses proliferation of MCF-7 breast cancer cells via activation of PPARγ and inhibition of ERK 1/2

AU - Moon, Hyun-Seuk

AU - Guo, Ding Ding

AU - Lee, Hong Gu

AU - Choi, Yun Jaie

AU - Kang, Jae Seong

AU - Jo, Kyungmin

AU - Eom, Jung Min

AU - Yun, Cheol Heui

AU - Cho, Chong Su

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Alpha-eleostearic acid (α-ESA) is known to suppress the growth in cancer cells although its underlying molecular mechanisms have not been fully elucidated. The present study was designed to elucidate and evaluate the anticancer mechanism of α-ESA on MCF-7 breast cancer cells. Also, an attempt was made to better understand the anticancer mechanism by which α-ESA activated PPARgamma; and attenuated the ERK1/2 MAPK phosphorylation state. The MCF-7 breast cancer cell-line and nontumorigenic MCF-10A human mammary epithelial cells were treated with α-ESA and compared with negative control (without treatment) and positive control groups (treated with rosiglitazone), and changes of apoptosis-related molecules, PPARgamma; and pERK1/2 were examined. In MCF-7 cells treated with α-ESA, we found that the expression of p53, p21, and Bax was up-regulated whereas expression of Bcl-2 and procaspase-9 was down-regulated. Moreover, nuclear translocation of PPARγ by α-ESA positively correlated with inhibition of ERK1/2 activation. Our data suggest that α-ESA can be considered to be a PPARgamma; agonist and thus a candidate for a chemotherapeutic agent against breast cancer.

AB - Alpha-eleostearic acid (α-ESA) is known to suppress the growth in cancer cells although its underlying molecular mechanisms have not been fully elucidated. The present study was designed to elucidate and evaluate the anticancer mechanism of α-ESA on MCF-7 breast cancer cells. Also, an attempt was made to better understand the anticancer mechanism by which α-ESA activated PPARgamma; and attenuated the ERK1/2 MAPK phosphorylation state. The MCF-7 breast cancer cell-line and nontumorigenic MCF-10A human mammary epithelial cells were treated with α-ESA and compared with negative control (without treatment) and positive control groups (treated with rosiglitazone), and changes of apoptosis-related molecules, PPARgamma; and pERK1/2 were examined. In MCF-7 cells treated with α-ESA, we found that the expression of p53, p21, and Bax was up-regulated whereas expression of Bcl-2 and procaspase-9 was down-regulated. Moreover, nuclear translocation of PPARγ by α-ESA positively correlated with inhibition of ERK1/2 activation. Our data suggest that α-ESA can be considered to be a PPARgamma; agonist and thus a candidate for a chemotherapeutic agent against breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=75649133232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75649133232&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2009.01389.x

DO - 10.1111/j.1349-7006.2009.01389.x

M3 - Article

VL - 101

SP - 396

EP - 402

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 2

ER -